Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Muscle MRI in a patient with chorea acanthocytosis.

Neuromuscular disorders : NMD·2026
Same author

Plasma phosphorylated tau and cerebrovascular burden predict emergency department use in dependent older patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Inter-centre heterogeneity, temporal evolution, and factors associated with treatment selection and outcomes in chronic inflammatory demyelinating polyradiculoneuropathy: a multicentre, combined prospective and retrospective observational study.

EClinicalMedicine·2026
Same author

Fluid biomarkers in cerebral amyloid angiopathy: current limitations and future directions.

Expert review of molecular diagnostics·2026
Same author

The novel (TCTG)<sub>n</sub> motif in CNBP expanded alleles: composition, dynamics and genotype-phenotype correlation in Myotonic dystrophy type 2 (DM2).

Human genomics·2026
Same author

Mitochondrial abnormalities in idiopathic inflammatory myopathies.

Clinical and experimental rheumatology·2026

Related Experiment Video

Updated: May 16, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Tetracyclines and neuromuscular disorders.

Daniele Orsucci1, Michelangelo Mancuso, Massimiliano Filosto

  • 1Department of Neuroscience, Neurological Clinic, University of Pisa, Italy, Via Roma.

Current Neuropharmacology
|December 4, 2012
PubMed
Summary

Tetracyclines show neuroprotective potential by inhibiting microglial activation and apoptosis. Further research is needed to confirm their efficacy and safety in treating neuromuscular disorders.

Keywords:
DoxycyclinePARP-1ROSminocyclinemitochondrianeurodegenerationprogressive external ophthalmoplegiatetracycline.

More Related Videos

Registration of Calcium Transients in Mouse Neuromuscular Junction with High Temporal Resolution using Confocal Microscopy
11:12

Registration of Calcium Transients in Mouse Neuromuscular Junction with High Temporal Resolution using Confocal Microscopy

Published on: December 1, 2021

Levator Auris Longus Preparation for Examination of Mammalian Neuromuscular Transmission Under Voltage Clamp Conditions
10:45

Levator Auris Longus Preparation for Examination of Mammalian Neuromuscular Transmission Under Voltage Clamp Conditions

Published on: May 5, 2018

Related Experiment Videos

Last Updated: May 16, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Registration of Calcium Transients in Mouse Neuromuscular Junction with High Temporal Resolution using Confocal Microscopy
11:12

Registration of Calcium Transients in Mouse Neuromuscular Junction with High Temporal Resolution using Confocal Microscopy

Published on: December 1, 2021

Levator Auris Longus Preparation for Examination of Mammalian Neuromuscular Transmission Under Voltage Clamp Conditions
10:45

Levator Auris Longus Preparation for Examination of Mammalian Neuromuscular Transmission Under Voltage Clamp Conditions

Published on: May 5, 2018

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neuromuscular Disorders

Background:

  • Tetracyclines possess neuroprotective properties, demonstrated in various neurological conditions.
  • Key mechanisms include inhibiting microglial activation, apoptosis, and reactive oxygen species.
  • The interplay between mitochondria, oxidative stress, and apoptosis is crucial for tetracycline's neuroprotective effects.

Purpose of the Study:

  • To review the neuroprotective effects of tetracyclines in animal models and human clinical studies.
  • To focus on the potential application of tetracyclines in patients with neuromuscular disorders.
  • To highlight the need for further research on optimal timing, dosage, and indications.

Main Methods:

  • Review of existing literature on tetracyclines in neurological and neuromuscular disorders.
  • Analysis of animal studies demonstrating neuroprotective effects.
  • Evaluation of clinical studies in humans, including those with neuromuscular conditions.

Main Results:

  • Tetracyclines exhibit neuroprotective effects in animal models of neurological disorders.
  • Evidence suggests potential benefits in amyotrophic lateral sclerosis, though clinical replication is lacking.
  • Further investigation is required for conditions like Guillain-Barré syndrome, neuropathies, muscular dystrophies, and mitochondrial disorders.

Conclusions:

  • Tetracyclines demonstrate promising neuroprotective mechanisms relevant to neurological and neuromuscular disorders.
  • Clinical evidence for efficacy in neuromuscular conditions is currently limited, necessitating more robust trials.
  • Well-designed, double-blind controlled trials are essential to establish the therapeutic role of tetracyclines.